Piper Sandler analyst Jessica Tassan raised the firm’s price target on Phreesia to $43 from $37 and keeps an Overweight rating on the shares. After a period of "opportunistic investment," the company has begun to recapture adjusted EBITDA margins, the analyst tells investors in a research note. The firm says a return to historical levels of employee productivity would put Phreesia fiscal 2025 targets "well within reach." Piper names the stock a top pick 2023.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHR:
- Piper Sandler healthcare tech analysts to hold analyst/industry conference call
- Phreesia named 2023 Top Pick, added to Conviction List at Needham
- Baird staying selective in vertical software, makes four rating changes
- Phreesia upgraded to Buy at Citi on ‘clearer path to profitability’
- Phreesia upgraded to Buy from Neutral at Citi